Analytical Data
-
Gene name
FGFR1OP2
- Application
-
Alternative Names
DKFZp564O1863; FGFR1 oncogene partner 2; FGFR1OP2; FGOP2_HUMAN; Fibroblast growth factor receptor 1 oncogene partner 2; HSPC123; HSPC123 like; WIT3.0; Wound inducible transcript 3.0
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NVK5
-
Expression Region
1-253aa
-
AA Sequence
MSCTIEKALADAKALVERLRDHDDAAESLIEQTTALNKRVEAMKQYQEEIQELNEVARHRPRSTLVMGIQQENRQIRELQQENKELRTSLEEHQSALELIMSKYREQMFRLLMASKKDDPGIIMKLKEQHSKIDMVHRNKSEGFFLDASRHILEAPQHGLERRHLEANQNELQAHVDQITEMAAVMRKAIEIDEQQGCKEQERIFQLEQENKGLREILQITRESFLNLRKDDASESTSLSALVTNSDLSLRKS
-
Molecular Weight
55.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FGFR1OP2 (Fibroblast Growth Factor Receptor 1 Oncogene Partner 2) is a gene that plays a crucial role in various cellular processes, including cell proliferation, differentiation, and survival. Its dysregulation has been implicated in several cancers, making it a significant subject of study in cancer research. FGFR1OP2 is known to interact with fibroblast growth factor receptors (FGFRs), influencing pathways that are critical for tumorigenesis. The interest in FGFR1OP2 recombinant proteins arises from the need to understand its biological functions in greater detail, as well as its potential as a therapeutic target. By generating FGFR1OP2 recombinant proteins, researchers aim to elucidate the molecular mechanisms underlying its role in cancer progression, investigate its interaction with other cellular components, and explore its utility in developing targeted therapies. These studies are pivotal for identifying novel biomarkers for cancer diagnosis and prognosis, as well as for designing innovative treatment strategies that could improve patient outcomes. Understanding FGFR1OP2's function at a molecular level could open avenues for targeted interventions in malignancies associated with its aberrant expression or function, thereby contributing to personalized medicine approaches in oncology.
